Education
About Us
Working with TipRanks
Follow Us
Inogen (INGN)
NASDAQ:INGN
Earnings Data
Report Date
Apr 30, 2026After Close (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
-0.29Last Year’s EPS
-0.25Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call presented a clear operational and strategic turnaround: mid-single-digit revenue growth, >20% unit growth, strong international momentum, return to adjusted EBITDA profitability for the year, a strengthened balance sheet with no debt and a $30M buyback authorization, and meaningful product diversification with early traction for new launches. Headwinds remain — notably U.S. sales and rental declines, gross margin compression from channel mix, timing shifts of large orders into H1 2026, and an ongoing GAAP net loss — but management provided guidance for continued adjusted EBITDA positivity, 2026 revenue growth (mid-single digits to ~6% at midpoint) and longer-term targets (high single-digit growth and ≥10% adjusted EBITDA in 3–5 years). Overall, the positive operational progress, profitability inflection, cash position and portfolio expansion outweigh the near-term channel and timing challenges.Company Guidance
Revenue Growth and Unit Volume Expansion
Q4 2025 revenue of $81.7M (approx. $82M) and full-year 2025 revenue of $348.7M, up 2% in Q4 and 4% for the year year-over-year; unit volumes grew >20% YoY in Q4 and for the full year, driven by POC demand and conversion from tanks to POCs.
International Business Strength
International Q4 revenue of $32.5M, up ~14.8%-15% YoY; full-year growth was primarily driven by international POC sales growing ~18.4%, with successful HME relationships and tenders expanding global presence.
Return to Adjusted EBITDA Profitability
Delivered positive adjusted EBITDA of $2.7M for full-year 2025 — first adjusted EBITDA profitability since 2021; Q4 adjusted EBITDA improved to negative $1.7M from negative $3.6M a year earlier.
Substantial Reduction in Adjusted Net Loss
Full-year adjusted net loss narrowed to $8.0M in 2025, a 60.6% improvement from $20.4M in 2024; GAAP net loss improved to $22.7M (down 36.6% YoY).
Strong Balance Sheet and Capital Return Plan
Ended 2025 with $120.9M in cash, equivalents, marketable securities and restricted cash, zero debt (up $3.4M vs 2024); Board authorized a $30M share repurchase program to be executed in 2026–2027.
Product Innovation and Portfolio Diversification
Expanded from a single-product POC company to a multi-product respiratory care platform (oxygen therapy, sleep therapy, airway clearance, digital health); launched Simeox limited release, Voxi 5 stationary concentrator, Aurora CPAP masks (FDA 510(k) cleared) and an Inogen patient portal.
Early Commercial Traction for New Products
Simeox generated >$6M global revenue in 2025 (primarily international, cash-pay) with positive clinical/commercial feedback; Voxi showed strong sequential growth post-launch; Aurora masks showed high patient satisfaction in studies and are being commercialized via B2B channels.
Expanded Addressable Market and Long-Term Targets
Estimated TAM expanded from ~$400M (POC only) to ~ $3.4B across the combined portfolio (airway clearance +$500M, Voxi +$300M, sleep masks ~$2.2B); management targets high single-digit revenue growth and ≥10% adjusted EBITDA within 3–5 years and plans to launch ≥1 new product per year.
Operating Expense Discipline
Q4 operating expenses $44.5M; adjusted operating expenses down to $41.4M from $43.7M a year earlier, a 5.2% reduction, reflecting cost management while investing in R&D and launches.
INGN Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
INGN Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Feb 24, 2026 | $5.84 | $6.01 | +2.91% |
Nov 05, 2025 | $8.06 | $7.39 | -8.31% |
Aug 07, 2025 | $5.87 | $6.48 | +10.39% |
May 07, 2025 | $7.17 | $6.35 | -11.44% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Inogen (INGN) report earnings?
Inogen (INGN) is schdueled to report earning on Apr 30, 2026, After Close (Confirmed).
What is Inogen (INGN) earnings time?
Inogen (INGN) earnings time is at Apr 30, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is INGN EPS forecast?
INGN EPS forecast for the fiscal quarter 2026 (Q1) is -0.29.